News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital
Non-dilutive funding vehicle strengthens balance sheet for registration filing of avacopan in ANCA vasculitis and anticipated approval and commercial launch MOUNTAIN VIEW, Calif. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (NASDAQ: CCXI) today announced that the Company has secured a
View HTML
Toggle Summary ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference
MOUNTAIN VIEW, Calif. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednesday January 15, 2020 at 1:30 p.m. PT .
View HTML
Toggle Summary ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference
MOUNTAIN VIEW, Calif. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 2:30 p.m. ET .
View HTML
Toggle Summary ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis
-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks --   -- Significantly reduced glucocorticoid toxicity -- -- Significantly improved kidney function compared to glucocorticoid-containing SOC
View HTML
Toggle Summary Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ACCOLADE Phase II Trial in C3G -- Reinforces Therapeutic Potential of Chemokine Receptor 2 (CCR2) Inhibition in the Treatment of FSGS -- MOUNTAIN VIEW, Calif. , Nov.
View HTML
Toggle Summary ChemoCentryx Reports Third Quarter 2019 Financial Results and Recent Highlights
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA vasculitis expected mid-to-late fourth quarter -- -- Awarded $1 million grant from the U.S. Food and Drug Administration ( FDA ), to support the ACCOLADE Phase II trial of avacopan in C3 Glomerulopathy
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2019 Financial Results Conference Call on Monday, November 4, 2019
MOUNTAIN VIEW, Calif. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2019 financial results will be released after market close on Monday, November 4, 2019 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx to Host R&D Day on October 1, 2019
MOUNTAIN VIEW, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that it will host an R&D Day on Tuesday, October 1, 2019 beginning at 12:00 p.m. ET in New York City . Key therapeutic areas of focus for the R&D Day will be ANCA-Associated Vasculitis
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September:              BioCentury Newsmakers in the Biotech
View HTML
Toggle Summary ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis on track for Q4 2019 -- -- Completed enrollment in LUMINA 1 Phase II trial of CCR2 inhibitor CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Advancing three additional clinical
View HTML